Marty Makary addresses staff concerns over drug voucher program
WASHINGTON — At an employee town hall on Tuesday, Food and Drug Administration leaders tried to quell staff…
Baseline, Roche, Intellia, Eli Lilly: Readout Newsletter
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter…
Roche moves obesity drug to pivotal trials after mid-stage success
Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at…
The new medicines and medical advances that defined 2025
It has been a tough year for medicine. The U.S. research enterprise has been scrambled by a series…
Pharma’s ‘Dr. Optimistic’ is worried about the industry’s future
In July 2006, The New York Times sent young reporter Alex Berenson to Pfizer to interview me about…
Mutual mistrust: FDA staff wary as Høeg becomes top drug regulator
WASHINGTON — In 2008, Tracy Beth Høeg, then a resident physician and ultramarathon runner, expressed dismay at vice…
FDA reviewers didn’t get to vote on first priority voucher drug
WASHINGTON — The Food and Drug Administration has promised companies that earn a Commissioner’s National Priority Voucher a one-…
AbbVie parts ways with Calico
Unexpected uncoupling raises questions about the pace – and patience – of longevity drug discovery amid shifting pharma…
Countries used to test drugs often don’t see the approved medicines, study finds
Numerous medicines are not accessible in many of the countries where they were tested before approval by the…
New FDA priority review vouchers go to Lilly, Novo, Vertex
WASHINGTON — The Food and Drug Administration on Thursday announced the second batch of companies being granted a “Commissioner’s…
Targeting heart health for post-menopausal women
The average lifespan of Canadian women is 83.9 years. They tend to start menopause between the ages of…
How a change in FDA guidance might revolutionise MASH drug development
Transformative new shifts have taken place in the last month in the metabolic dysfunction-associated steatohepatitis (MASH) therapy space,…